Current GVHD-Free, Relapse-Free Survival – a Dynamic Endpoint to Better Define Efficacy Following Allogenic Transplant

Highlights • CGRFS is a novel composite endpoint which attempts to incorporate the most important elements of transplant success. • It acknowledges the important impact that clinically-significant ongoing GVHD has on the quality of life of long-term survivors

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2017
Main Authors: Solomon, Scott R., MD, Sizemore, Connie, Pharm.D, Zhang, Xu, PhD, Ridgeway, Michelle, Solh, Melhem, MD, Morris, Lawrence E., MD, Holland, H. Kent, MD, Bashey, Asad, MD, PhD
Format: Article
Language:English
Subjects:
Hematology, Oncology and Palliative Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • CGRFS is a novel composite endpoint which attempts to incorporate the most important elements of transplant success. • It acknowledges the important impact that clinically-significant ongoing GVHD has on the quality of life of long-term survivors
ISSN:1083-8791
DOI:10.1016/j.bbmt.2017.02.022